ZIOPHARM Oncology

ZIOPHARM Oncology, Inc., is a biopharmaceutical company focused on the discovery and development of new cancer therapies. We are applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.
Company Growth (employees)
Type
Public
HQ
Boston, US
Size (employees)
36 (est)
ZIOPHARM Oncology is headquartered in Boston, US

Key People/Management at ZIOPHARM Oncology

Jonathan Lewis

Jonathan Lewis

CEO
Caesar J. Belbel

Caesar J. Belbel

CLO

ZIOPHARM Oncology Office Locations

ZIOPHARM Oncology has an office in Boston
Show all (1)

ZIOPHARM Oncology Financials and Metrics

ZIOPHARM Oncology Financials

ZIOPHARM Oncology's revenue was reported to be $6.9 m in FY, 2016
USD

Net income (Q3, 2017)

(12.7 m)

EBIT (Q3, 2017)

(13.1 m)

Market capitalization (22-Dec-2017)

569.6 m

Cash (30-Sep-2017)

84.4 m
ZIOPHARM Oncology's current market capitalization is $569.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

800 k1.4 m4.3 m6.9 m

Revenue growth, %

72%216%58%

R&D expense

157.8 m

General and administrative expense

14.4 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

R&D expense

12 m10.8 m

General and administrative expense

3.1 m3.4 m3 m2.8 m4.3 m7.1 m3.1 m3.8 m3.7 m3.5 m3.6 m3.8 m

Operating expense total

9.3 m10 m11.4 m12.6 m78.5 m14.5 m20 m14 m132.9 m12.5 m15.6 m14.6 m14.7 m

EBIT

(9.1 m)(9.8 m)(11.2 m)(11.9 m)(78.2 m)(14.2 m)(18.2 m)(12 m)(131.2 m)(10.9 m)(14 m)(13 m)(13.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

68.2 m42.8 m140.7 m81.1 m

Accounts Receivable

508.4 m

Inventories

1.9 m1.1 m11.4 m23.8 m

Current Assets

70.3 m44.1 m152.5 m104.9 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

23.6 m60.4 m53 m46.1 m129.7 m118.6 m163.8 m124.8 m109 m94.7 m66.4 m97.2 m84.4 m

Inventories

30.5 m

Current Assets

27.3 m62 m54 m47.8 m130.6 m123.1 m172.5 m140.4 m126.7 m115.7 m92.8 m125.1 m114.9 m

PP&E

1.3 m679 k683 k654 k426 k321 k262 k667 k682 k825 k1.1 m1.1 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (57.1 m)(31.8 m)(120.1 m)(165.3 m)

    Depreciation and Amortization

    738 k462 k357 k290 k

    Inventories

    5 m809 k(10 m)(12 m)

    Accounts Payable

    (1.1 m)1.6 m4 k(1.9 m)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (48.2 m)(9.7 m)(15.3 m)(21.4 m)(78.2 m)(92.4 m)(110.6 m)(12 m)(143.2 m)(154.1 m)(15.5 m)(28.3 m)(12.7 m)

    Depreciation and Amortization

    582 k124 k217 k339 k122 k236 k295 k72 k155 k227 k79 k167 k

    Inventories

    30.5 m

    Accounts Payable

    (618 k)156 k25 k1.5 m(1.2 m)1.1 m2.2 m(100 k)23 k(194 k)70 k(75 k)1.5 m
      Y, 2017

      Financial Leverage

      -1.5 x
      Show all financial metrics

      ZIOPHARM Oncology Market Value History

      ZIOPHARM Oncology's Web-traffic and Trends

      ZIOPHARM Oncology Company Life and Culture

      You may also be interested in